BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yas E, Kelmer G, Shipov A, Ben-oz J, Segev G. Successful transendoscopic oesophageal mass ablation in two dogs with Spirocerca lupi associated oesophageal sarcoma. J Small Anim Pract 2013;54:495-8. [DOI: 10.1111/jsap.12076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Scansen BA. Interventional Radiology. Veterinary Clinics of North America: Small Animal Practice 2016;46:535-52. [DOI: 10.1016/j.cvsm.2015.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Shipov A, Kelmer G, Lavy E, Milgram J, Aroch I, Segev G. Long-term outcome of transendoscopic oesophageal mass ablation in dogs with Spirocerca lupi -associated oesophageal sarcoma. Veterinary Record 2015;177:365-365. [DOI: 10.1136/vr.103356] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Culp WTN, Griffin MA. Veterinary Clinics: Tumor Ablation. Vet Clin North Am Small Anim Pract 2019;49:949-66. [PMID: 31202538 DOI: 10.1016/j.cvsm.2019.04.007] [Reference Citation Analysis]
4 Pazzi P, Kavkovsky A, Shipov A, Segev G, Dvir E. Spirocerca lupi induced oesophageal neoplasia: Predictors of surgical outcome. Vet Parasitol 2018;250:71-7. [PMID: 29329628 DOI: 10.1016/j.vetpar.2017.11.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
5 Makielski KM, Mills LJ, Sarver AL, Henson MS, Spector LG, Naik S, Modiano JF. Risk Factors for Development of Canine and Human Osteosarcoma: A Comparative Review. Vet Sci 2019;6:E48. [PMID: 31130627 DOI: 10.3390/vetsci6020048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
6 Aroch I, Markovics A, Mazaki-Tovi M, Kuzi S, Harrus S, Yas E, Baneth G, Bar-El M, Bdolah-Abram T, Segev G, Lavy E. Spirocercosis in dogs in Israel: A retrospective case-control study (2004-2009). Vet Parasitol 2015;211:234-40. [PMID: 26012861 DOI: 10.1016/j.vetpar.2015.05.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
7 Segev G, Rojas A, Lavy E, Yaffe M, Aroch I, Baneth G. Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study. Parasit Vectors 2018;11:127. [PMID: 29506575 DOI: 10.1186/s13071-018-2731-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Beugnet F, Crafford D, de Vos C, Kok D, Larsen D, Fourie J. Evaluation of the efficacy of monthly oral administration of afoxolaner plus milbemycin oxime (NexGard Spectra(®), Merial) in the prevention of adult Spirocerca lupi establishment in experimentally infected dogs. Vet Parasitol 2016;226:150-61. [PMID: 27514901 DOI: 10.1016/j.vetpar.2016.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]